Dayvigo (Lemborexant) Dosing in Black and African Ancestry Patients: What the Evidence Actually Shows

What Is Lemborexant and Why Does Ancestry Matter for Dosing?

Lemborexant is a dual orexin receptor antagonist (DORA) that blocks OX1R and OX2R, reducing wake-promoting signaling to allow sleep onset and maintenance. The FDA approved it in December 2019 for adult insomnia disorder at doses of 5 mg and 10 mg taken no more than 30 minutes before bed [1].

Ancestry matters for lemborexant dosing primarily because of pharmacogenomic variation in CYP3A enzymes, which drive the drug's hepatic clearance. Populations of African descent carry a higher frequency of the CYP3A5*1 (expressor) allele compared with people of European descent [2]. That difference does not automatically require a dose change, but it does influence the drug's exposure profile and must be factored in alongside co-prescriptions that are statistically more common in Black patients, particularly antihypertensives and certain antiretrovirals.

CYP3A4 vs. CYP3A5: Why Both Enzymes Matter

Lemborexant is metabolized predominantly by CYP3A4, with CYP3A5 playing a secondary role. In individuals who express CYP3A5 at high levels (CYP3A5*1/*1 or CYP3A5*1/*3 genotypes), total CYP3A activity is higher, which may lower steady-state lemborexant plasma concentrations modestly [3]. The FDA label notes that strong CYP3A4 inducers are contraindicated with lemborexant and that moderate CYP3A4 inhibitors require a dose cap of 5 mg [1].

Population Allele Frequencies in African Ancestry Groups

The CYP3A5*1 allele frequency is approximately 52 to 73% in sub-Saharan African-ancestry populations, compared with roughly 4 to 10% in Europeans and 15 to 25% in East Asians [2]. This means roughly two in three African-ancestry patients are CYP3A5 high-expressers rather than one in four European-ancestry patients. No published pharmacokinetic bridging study has specifically enrolled African-ancestry participants to quantify the magnitude of lemborexant exposure difference, which is a gap clinicians should recognize.

SUNRISE-1 and SUNRISE-2: What the Phase 3 Trials Actually Showed

The key evidence for lemborexant comes from SUNRISE-1 (NCT02783729) and SUNRISE-2 (NCT02952820). SUNRISE-1 was published in JAMA Network Open in 2019 and enrolled 291 adults with insomnia disorder, comparing lemborexant 5 mg, lemborexant 10 mg, and zolpidem extended-release 6.25 mg against placebo over 30 nights [4].

Primary Endpoints in SUNRISE-1

Lemborexant 5 mg reduced latency to persistent sleep (LPS) by 17.2 minutes vs. Placebo (P<0.0001) and lemborexant 10 mg reduced LPS by 22.2 minutes vs. Placebo (P<0.0001) at day 1 [4]. Wake after sleep onset (WASO) improvements were sustained across the 30-night treatment period for both doses.

Racial and Ethnic Subgroup Representation

SUNRISE-1 enrolled a predominantly White population, as the published subgroup tables indicate. Black or African American participants constituted fewer than 10% of the total SUNRISE-1 sample, consistent with the broader underrepresentation of Black patients in insomnia pharmacotherapy trials [4]. This enrollment gap means no statistically powered race-stratified efficacy or safety subgroup data exist for lemborexant. Clinicians cannot assume the primary endpoint magnitudes translate identically across ancestry groups, though the mechanism of action (orexin receptor blockade) is not known to differ by race.

SUNRISE-2 and Longer-Term Data

SUNRISE-2 (N=949, 12 months) confirmed durable efficacy for both doses and found no differential discontinuation signal across race categories in its descriptive summaries, though the trial was similarly underpowered for race-stratified analysis [5]. The FDA summary review for lemborexant, available via FDA.gov, did not identify safety signals specific to Black patients in the pooled clinical program [1].

Pharmacogenomics: CYP3A5 Expression and Lemborexant Clearance

CYP3A5 high-expressers metabolize certain substrates faster, potentially reducing drug exposure. PharmGKB lists lemborexant as a CYP3A4 substrate and notes the potential for CYP3A5 to contribute to interindividual variability, though no specific gene-drug pair annotation with high evidence level exists for lemborexant at this time [3].

What Higher CYP3A5 Expression Might Mean Clinically

If a patient of African ancestry carries CYP3A5*1/*1 and experiences subjective under-efficacy at 5 mg without a concurrent CYP3A4 inhibitor on their medication list, up-titration to 10 mg is both the guideline-consistent and pharmacologically rational next step [1]. The FDA label already permits this titration based on tolerability, making ancestry-informed reasoning compatible with approved prescribing practice.

When CYP3A5 Reasoning Is Overridden by Drug Interactions

A Black patient taking diltiazem (a moderate CYP3A4 inhibitor used commonly in hypertension and rate control) and lemborexant should be capped at 5 mg per FDA labeling, regardless of CYP3A5 genotype [1]. Diltiazem is among the most prescribed antihypertensives in African American adults with hypertension and heart failure [6]. That clinical reality means the CYP3A4 interaction scenario is not a theoretical edge case, it is a frequent clinical configuration in this population.

CYP3A4 Inhibitor Classes Frequently Prescribed in African-Ancestry Patients

Several drug categories with disproportionately high use in Black patients also carry CYP3A4 inhibitory potential:

• Calcium channel blockers (diltiazem, verapamil): moderate CYP3A4 inhibitors; require lemborexant 5 mg cap [1]
• Azole antifungals (fluconazole, itraconazole): moderate to strong inhibitors; fluconazole requires 5 mg cap, strong azoles contraindicate combination [1]
• HIV antiretrovirals (ritonavir-boosted regimens): strong CYP3A4 inhibitors; co-administration is contraindicated [1]
• Certain macrolides (clarithromycin): strong CYP3A4 inhibitors; co-administration is contraindicated [1]

The higher prevalence of HIV in African-ancestry communities in the United States, the CDC reports that Black Americans represented 40% of new HIV diagnoses in 2022 despite being approximately 14% of the U.S. Population [7], makes the antiretroviral interaction point clinically non-trivial.

Comorbidities That Shape Lemborexant Dosing in This Population

Hypertension and Cardiovascular Disease

Hypertension affects roughly 57% of Black adults in the United States, a rate approximately 10 percentage points higher than in White adults, per the American Heart Association's 2024 statistical update [8]. Patients on complex antihypertensive regimens may be taking diltiazem or verapamil, both of which interact with lemborexant. A thorough medication reconciliation before initiating Dayvigo is essential in this population.

Lemborexant itself does not carry a cardiovascular contraindication. Orexin receptor antagonists as a class have not shown clinically significant effects on blood pressure in trial populations [4]. The interaction risk flows from the antihypertensives, not from lemborexant's direct cardiovascular pharmacology.

Chronic Kidney Disease

Black Americans develop end-stage renal disease at approximately 3.4 times the rate of White Americans, driven in part by higher rates of hypertensive nephrosclerosis and APOL1 risk-variant carriage [9]. The FDA label states that no dose adjustment of lemborexant is required for renal impairment, including severe renal impairment [1]. Clinicians managing African-ancestry patients with CKD can use the standard 5 mg to 10 mg range without renal-based restriction, though polypharmacy burden in CKD patients warrants careful interaction review.

Hepatic Impairment

Lemborexant is contraindicated in severe hepatic impairment (Child-Pugh C). In mild-to-moderate hepatic impairment (Child-Pugh A or B), the dose must not exceed 5 mg [1]. Non-alcoholic fatty liver disease prevalence differs by ancestry, but this labeling constraint applies uniformly regardless of race.

G6PD Deficiency

The prevalence of G6PD deficiency is approximately 10 to 15% in African-ancestry males [10]. G6PD status has no direct pharmacodynamic or pharmacokinetic relevance to lemborexant, which does not generate oxidative metabolites that stress the hexose monophosphate shunt. Its clinical relevance here is indirect: a patient with G6PD deficiency may face constraints on which co-medications they can take, altering the overall drug-interaction calculus around lemborexant.

The FDA Label: What It Says and What It Does Not Say

The prescribing information for Dayvigo, available on the FDA's electronic label repository, does not include any race-specific dose guidance [1]. The document covers:

• Starting dose: 5 mg no more than once per night
• Maximum dose: 10 mg per night
• Contraindications: narcolepsy; strong CYP3A4 inhibitors; severe hepatic impairment
• Moderate CYP3A4 inhibitors: cap dose at 5 mg
• Moderate CYP3A4 inducers: avoid combination
• Strong CYP3A4 inducers: contraindicated

The American Academy of Sleep Medicine's 2017 clinical practice guideline for chronic insomnia in adults, updated with supplementary DORA guidance, states that orexin receptor antagonists are appropriate first-line pharmacotherapy options, though prescribers should individualize selection based on patient comorbidities and medications [11]. No AASM guidance stratifies DORA dosing by race.

Practical Prescribing Recommendations for Black and African Ancestry Patients

Step 1: Medication Reconciliation First

Before writing the first prescription, confirm whether the patient is taking any moderate or strong CYP3A4 inhibitor. Pay particular attention to diltiazem, verapamil, fluconazole, and any ritonavir-containing HIV regimen. If a moderate inhibitor is present, start and cap at 5 mg. If a strong inhibitor is present, do not prescribe lemborexant.

Step 2: Start at 5 mg

Start at 5 mg regardless of ancestry. The FDA label and SUNRISE-1 data support 5 mg as effective in reducing LPS and WASO [4]. Many patients achieve adequate sleep improvement at this dose.

Step 3: Titrate to 10 mg If Needed

If the patient reports insufficient benefit at 5 mg after 7 to 14 nights and tolerates the drug well, titrate to 10 mg. In a CYP3A5 high-expresser (which many African-ancestry patients are) without a concurrent CYP3A4 inhibitor, 10 mg is pharmacologically rational and within label [1].

Step 4: Monitor for Next-Day Somnolence

SUNRISE-1 data showed that somnolence and fatigue were more frequent with lemborexant 10 mg than 5 mg [4]. In patients with demanding daytime jobs, operating motor vehicles, or caring for dependents, this risk-benefit discussion should be explicit. The FDA label includes a boxed warning class-level caution about complex sleep behaviors with all approved sleep agents, though this is not race-specific.

Step 5: Reassess at 30 Days

Reassess subjective sleep quality, daytime function, and any adverse effects at the 30-day mark. SUNRISE-2 data confirmed that 12-month continuous use was associated with maintained efficacy without tolerance development for most participants [5].

Gaps in the Evidence Base

The single most important limitation in this area is the absence of a published, adequately powered pharmacokinetic study of lemborexant in a cohort enriched for African ancestry. The FDA's Drug Trials Snapshots for lemborexant, released at the time of approval, confirmed underrepresentation of Black participants in the clinical program [1]. The NIH's National Institute on Minority Health and Health Disparities has identified sleep disparities as a research priority, noting that Black Americans report shorter sleep duration and higher rates of sleep-disordered breathing compared with White Americans, making this pharmacokinetic gap all the more clinically relevant [12].

Until ancestry-stratified pharmacokinetic data exist, clinicians should rely on:

1. Standard label-based dose titration (5 mg to 10 mg)
2. Systematic CYP3A4 inhibitor screening
3. Hepatic function assessment
4. Clinical response monitoring at 2 and 4 weeks

The Endocrine Society and AACE have both called for ethnicity-stratified reporting in drug trials as a standard expectation for submissions to regulatory bodies, a position that applies to sleep pharmacotherapy as much as any other therapeutic area [13].